JAGUAR HEALTH, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
JAGUAR HEALTH, INC. (JAGX) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $210.00 thousand as of 2025-12-31, per its 10-K filed 2026-04-07.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-04-07
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $210.00K.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $419.00K.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $559.00K.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.04M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $210.00K 10-K · filed 2026-04-07 | |
| 2024-12-31 | $419.00K 10-K · filed 2026-04-07 | |
| 2023-12-31 | $559.00K 10-K · filed 2025-03-31 | |
| 2022-12-31 | $3.04M 10-K · filed 2024-04-01 | |
| 2021-12-31 | $2.16M 10-K · filed 2023-03-24 | |
| 2020-12-31 | $1.71M 10-K · filed 2022-03-11 | $1.71K 10-K · filed 2021-03-31 |
| 2019-12-31 | $1.36K 10-K · filed 2021-03-31 | $1.36M 10-K · filed 2020-04-03 |
| 2018-12-31 | $1.48M 10-K · filed 2020-04-03 | |
| 2017-12-31 | $1.20M 10-K · filed 2019-04-10 | |
| 2016-12-31 | $297.44K 10-K · filed 2018-04-09 | |
| 2015-12-31 | $188.60K 10-K · filed 2017-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |